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Malaria and invasive non-typhoidal Salmonella (NTS) are life-threatening infections that 
often co-exist in African children. The iron-regulatory hormone hepcidin is highly 
upregulated during malaria and controls the availability of iron, a critical nutrient for bacterial 
growth. We investigated the relationship between Plasmodium falciparum malaria and NTS 
bacteremia in all pediatric admissions aged ≤5 years between August 1998 and October 2019 
(n=75,034). We then assayed hepcidin and measures of iron status in five groups: (1) children 
with concomitant severe malarial anemia (SMA) and NTS (SMA+NTS, n=16); and in 
matched children with (2) SMA (n=33); (3) NTS (n=33); (4) cerebral malaria (CM, n=34); 
and (5) community-based children. SMA and severe anemia without malaria were associated 
with a two-fold or more increased risk of NTS bacteremia, while other malaria phenotypes 
were not associated with increased NTS risk. Children with SMA had lower hepcidin/ferritin 
ratios (0.10 [IQR 0.03, 0.19]) than those with CM (0.24 [0.14, 0.69]; P=0.006) or 
asymptomatic malaria (0.19 [0.09, 0.46]; P=0.01) indicating suppressed hepcidin levels. 
Children with SMA+NTS had lower hepcidin levels (9.3 ng/mL [4.7, 49.8]) and 
hepcidin/ferritin ratios (0.03 [0.01, 0.22]) than those with NTS alone (105.8 ng/mL [17.3, 
233.3]; P=0.02 and 0.31 [0.06, 0.66]; P=0.007, respectively). Since hepcidin degrades 
ferroportin on the Salmonella-containing vacuole (SCV), we hypothesize that reduced 
hepcidin in children with SMA might contribute to NTS growth by modulating iron 
availability for bacterial growth. Further studies are needed to understand how the hepcidin-






Malaria and invasive non-typhoidal Salmonella (NTS) are major causes of illness and death 
among children living in sub-Saharan Africa. According to the World Health Organization 
(WHO), 94% of the 409,000 malaria-associated deaths in 2019 occurred in the sub-Saharan 
African region, with children under five years of age being disproportionately vulnerable.1 In 
this region, NTS bacteremia is also common accounting for 80% of the estimated 535,000 
global cases in 2017.2 While NTS is commonly associated with self-limiting gastroenteritis in 
European populations, NTS infections in African children can cause life-threatening sepsis 
with case fatality rates of 20-25%.2, 3 NTS bacteremia is highly prevalent in areas with 
concurrent malaria endemicity,4-6 and reduced malaria incidence has been associated with a 
decrease in NTS bacteremia.7, 8 The association between NTS and malaria has been 
particularly observed in children with severe malarial anemia (SMA),5, 9-11 but this has not 
been reported in all settings.12, 13 
 
SMA may increase susceptibility to NTS bacteremia via a number of contributory pathways 
including sustained hemolysis, accumulation of free heme from lysed red blood cells, 
increased gut permeability, disruption of immune responses, and upregulation of heme 
oxygenase-1 (Figure 1).14 Heme oxygenase-1 impairs neutrophil oxidative burst capacity, 
reduces neutrophil bactericidal activity, and promotes iron accumulation in macrophages.15, 16 
Recent in vitro and animal studies suggest that hepcidin, the master iron regulator17, may also 
play an important role in determining susceptibility to NTS by controlling the availability of 
iron,18-20 a nutrient critical for bacterial growth and proliferation.16, 19 Hepcidin degrades 
ferroportin, the sole iron exporter, which was recently shown to transport iron across the 
Salmonella-containing vacuole (SCV).21, 22 In murine studies, low hepcidin levels and 




Salmonella Typhimurium infections (Figure 1).18, 22 However, there are no studies of 
hepcidin in NTS infection in humans. In this study, we investigated the relationship between 
malaria, anemia and NTS in 75,034 hospitalized Kenyan children over a 21-year period and 




Study design and participants 
Ethical approval was granted by the Scientific Ethics Review Unit of the Kenya Medical 
Research Institute and informed consent was provided by parents or guardians 
(Supplementary Methods). The study was conducted in Kilifi, a rural malaria-endemic area 
along the Kenyan coast. The estimated incidence rate of NTS bacteremia among children <5 
years was 36.6 cases/100,000 person-years between 1998 to 2014.23 Our study included two 
parts:  
1. We investigated the relationship between malaria and NTS bacteremia among all 
pediatric admissions (n=75,034) aged ≤60 months admitted between 1st August 1998 and 
31st October 2019 with complete age, malaria and hemoglobin data.  
2. We then measured hepcidin, iron and inflammatory markers from five groups of children 
including those hospitalized with: 1) SMA and NTS coinfection (SMA+NTS); 2) SMA 
alone; 3) NTS alone; and 4) cerebral malaria (CM) and 5) community-based children 
with and without asymptomatic malaria using stored biobank samples over the 21-year 
time period. Each child from group 1 was matched with two from each of the other 
hospitalized groups based on age and sex (Figure 2). The community-based children 
were part of an ongoing birth cohort evaluating malaria immunity,24 and their samples 






Thick and thin blood films were stained with Giemsa and examined for Plasmodium 
falciparum using standard methods. Samples for bacterial culture were collected in 
BACTEC® Peds Plus bottles and processed with a BACTEC-8050 automated blood-culture 
instrument (Becton-Dickson, UK). Positive samples were sub-cultured and serological tests 
and biochemical test kits (API, bioMérieux) were used to confirm suspected pathogens.23, 25 
Bacillus species, Micrococcus species, viridans group Streptococcus, coagulase negative 
Staphylococcus, and coryneforms were considered contaminants. Rapid antibody tests were 
used for HIV-1 testing. Sickle cell disease was diagnosed using polymerase chain reaction 
(Supplementary Methods). Iron and inflammatory biomarkers were assayed as previously 
described26 (Supplementary Methods). 
 
Clinical definitions 
For children with Plasmodium falciparum malaria, we defined SMA as hemoglobin <5 g/dl 
and CM as Blantyre coma score <3 according to WHO criteria.27 Severe anemia was defined 
as hemoglobin <5 g/dl; fever as temperature >37.5C; and NTS bacteremia as isolation of 
Salmonella enterica subspecies excluding Typhi or Paratyphi serovars in blood cultures.  
 
Statistical analyses 
All data were analyzed using STATA 15.1 (StatCorp. College Station, Texas, USA). For all 
pediatric admissions, we used univariable and multivariable logistic regression models to 
investigate for putative risk factors for NTS bacteremia. We used a causal directed acyclic 
graph to assess the suitability of covariates for multivariable analyses (Supplementary Figure 




models (Supplementary Methods). We also analyzed the relationship between SMA and risk 
of other bacterial organisms. In the hepcidin sub-study, continuous data were reported as 
medians and interquartile ranges (IQR) and compared using the Wilcoxon rank-sum test. 
Non-parametric Spearman’s correlation evaluated associations between variables. We 
normalized nonnormally-distributed variables by loge-transformation and used multivariable 




Study of all hospital admissions 
A total of 75,034 children aged ≤60 months were admitted to Kilifi County Hospital during 
the 21-year study period and had complete data for analysis. Median age was 11.8 months 
(IQR 2.2, 26.1) and 42,450 (56.6%) were male. P. falciparum malaria was identified in the 
blood films of 16,463 (21.9%) hospitalized children; of whom 2,291 (13.9%) had SMA, 
1,727 (10.5%) had CM, and 416 (2.5%) had concomitant SMA and CM. Pathogenic bacterial 
organisms were isolated from 3,792 (5.1%) blood cultures. NTS bacteremia was identified in 
400 (10.5%) of the positive blood cultures. Of the NTS isolates, 309 were serotyped and 
45.0% (139/309) were Salmonella enterica serovar Enteritidis and 44.3% (137/309) were 
serovar Typhimurium, while 10.7% (33/309) were not typeable. The prevalence of NTS 
bacteremia has decreased over the years as malaria has also decreased (Supplementary Figure 
S2). 
 
NTS bacteremia was identified in 93/16,463 (0.6%) hospitalized children with P. falciparum 
malaria, including 38/2,291 (1.7%) with SMA and 8/1,727 (0.5%) with CM. SMA was 




(adj. OR 2.17 [95% CI 1.44, 3.28]; P=0.0002, Supplementary Table S2). However, a positive 
malaria slide (OR 1.08 [95% CI 0.85, 1.36]; P=0.52) and CM (OR 1.00 [95% CI 0.50, 2.02]; 
P=0.99) were not associated with increased risk of NTS bacteremia (Table 1). Children with 
malaria but without SMA had a 39% reduced risk of NTS bacteremia (OR 0.61 [95% CI 
0.45, 0.82]; P=0.001, Table 1). Children with severe anemia without malaria parasitemia also 
had an increased risk of NTS bacteremia in final multivariable models (adj. OR 4.03 [95% CI 
2.78, 5.84]; P<0.0001, Supplementary Table S2). The risk of NTS bacteremia increased by 
26% for each 1 g/dL decrease in hemoglobin levels in all children (adj. OR 1.26 [95% CI 
1.21, 1.32]; P<0.0001) and by 51% in children with malaria parasitemia (adj. OR 1.51 [95% 
CI 1.36, 1.68]; P<0.0001). In final multivariable models, other significant risk factors for 
NTS bacteremia were younger age, fever, diarrhea, sickle cell disease, very severe 
pneumonia, underweight and, in restricted models, HIV status (Supplementary Table S2). 
SMA was not associated with increased risk of other bacterial organisms causing bacteremia 
(Supplementary Figure S3).  
 
Hepcidin sub-study  
We included 116 hospitalized children in the following groups: 1) 16 with SMA+NTS; 2) 33 
with SMA alone; 3) 33 with NTS alone; and 4) 34 with CM (Figure 2); and 5) 291 
community-based children with (n=49) and without (n=242) asymptomatic malaria 
parasitemia. The clinical characteristics of children in the sub-study are shown in 
Supplementary Table S3.  
 
Hepcidin levels in children with malaria 
We first compared hepcidin levels among children with malaria. Hepcidin levels were lower 




ng/ml [IQR 38.7, 176.1]; P=0.002). However, both of these severe malaria groups had higher 
hepcidin levels than children with asymptomatic malaria parasitemia living in the community 
(Figure 3A). We found similar hepcidin levels in community-based children with and without 
asymptomatic malaria parasitemia (6.5 ng/ml [IQR 2.0, 13.1] and 3.8 ng/ml [IQR 1.2, 12.6], 
respectively). Hepcidin expression was suppressed in children with SMA as evidenced by a 
lower hepcidin/ferritin ratio (0.10 [IQR 0.03, 0.19]) compared to those with CM (0.24 [IQR 
0.14, 0.69]; P=0.006), or asymptomatic parasitemia (0.19 [IQR 0.09, 0.46]; P=0.01; Figure 
3B). 
 
We then explored differences in putative regulators of hepcidin. Children with SMA had 
increased erythropoietic drive as indicated by higher sTfR levels (43.3 mg/L [IQR 30.8, 
65.6]) than those with CM (31.2 mg/L [IQR 23.9, 45.5]; P=0.03), although ferritin and CRP 
levels did not differ between the groups (Figure 3). Hospitalized children had higher levels of 
ferritin, sTfR, and CRP and higher P. falciparum parasite densities than those living in the 
community (Figure 3 C-F). 
 
Hepcidin levels in children with malaria and NTS 
We then considered hepcidin levels in children with malaria and NTS. Hepcidin levels were 
lower in children with SMA+NTS (9.3 ng/ml [IQR 4.7, 49.8]) compared to those with NTS 
alone (105.8 ng/ml [IQR 17.3, 233.3]; Figure 4A, Table 2). Hepcidin/ferritin ratios were also 
lower in children with SMA+NTS (0.03 [IQR 0.01, 0.22]) compared to those with NTS alone 
(0.31 [IQR 0.06, 0.66]; P=0.007; Table 2, Figure 4B). In a linear regression model controlled 
for CRP and year of admission, hepcidin levels were two-fold higher in children with NTS 
compared to those with SMA+NTS (adj. β 1.99 [95% CI 0.81, 3.26]; P=0.001, Supplementary 




C-E). Only one participant in the sub-study had sickle cell disease and excluding the 
participant from the analysis did not alter our findings.  
 
Hepcidin levels were positively correlated with ferritin (r=0.38, P=0.0001), CRP (r=0.31, 
P=0.0007), hemoglobin (r=0.37, P<0.0001) and parasite density (r=0.44, P<0.0001),  and 
negatively correlated with sTfR (r=-0.37, P<0.0001) among the hospitalized children.The 
direction and strength of correlation between hepcidin and its predictors varied across 
individual groups as shown in Supplementary Table S5.  
 
Discussion 
Malaria and NTS are important causes of hospitalization and death among children living in 
sub-Saharan Africa.1, 2 In this study, we analyzed retrospective data from 75,034 hospitalized 
children aged ≤60 months and found that SMA, but not CM or other malaria phenotypes, was 
associated with increased risk of NTS bacteremia. Children with severe anemia of all causes, 
both with or without malaria parasitemia, also had an increased risk of NTS bacteremia. In a 
sub-study investigating iron biomarkers, children with SMA had lower hepcidin levels than 
children with CM. We also found that children with SMA+NTS had lower hepcidin levels 
than children with NTS alone. We did not find differences in ferritin or CRP levels among 
hospitalized children, but children with SMA alone and SMA+NTS had lower 
hepcidin/ferritin ratios and higher sTfR levels. Children living in the community with 
asymptomatic parasitemia had lower levels of hepcidin, ferritin, CRP and sTfR and lower 
parasite densities than hospitalized children.   
 
Children with SMA had a two-fold increased risk of NTS bacteremia compared to those 




that excluded severe anemia. Moreover, each 1g/dl decrease in hemoglobin concentrations in 
children with malaria was associated with a 51% increase in the risk of NTS bacteremia. 
SMA increased the risk of NTS, but not other bacteria suggesting an NTS-specific effect 
rather than a generalized immunological failure to control bacteremia (Supplementary Figure 
S3). Previous studies across sub-Saharan Africa have also reported an increased risk of NTS 
bacteremia in children with SMA,5, 9, 10 but not CM.10, 28 A study in Malawian children with 
severe malaria reported a 43% increase in the risk of NTS bacteremia per 1g/dl reduction in 
hemoglobin levels.9 However, these observations have not been universal. A study in 
Mozambican children reported no clear-cut association between SMA and NTS bacteremia, 
although few children had NTS bacteremia (n=12).13 In agreement with the current study, 
previous studies have found no association between malaria and risk of NTS bacteremia,4, 23 
although other studies have reported mixed findings with malaria both reducing and 
increasing risk of NTS bacteremia29-32. These differences might be explained by the 
prevalence of malarial anemia within the study populations or various other factors, including 
nutritional status. Taken together, our findings suggest that SMA, rather than other malarial 
phenotypes, underlies the association between malaria and NTS bacteremia. Indeed, severe 
anemia due to all causes was strongly associated with NTS bacteremia, even after excluding 
children with malaria parasitemia, in agreement with a previous study in Malawian 
children.33 
 
A number of pathways may contribute to increased risk of NTS bacteremia in children with 
SMA including hemolysis, iron overload and upregulation of heme oxygenase-1 (Figure 1).14 
Hepcidin may also influence risk of NTS bacteremia in SMA by controlling the availability 
of iron for bacterial growth.18-20 We observed that hepcidin levels and hepcidin/ferritin ratios 




study in Kenyan children found lower hepcidin levels in malaria patients with severe anemia 
compared to those with higher hemoglobin levels.34 In contrast, a study in Nigerian children 
found no difference in hepcidin levels between children with SMA and CM and higher 
hepcidin levels in uncomplicated compared to severe malaria.35 Our findings may be 
explained by the low hepcidin/ferritin ratio and higher sTfR levels in SMA compared to CM, 
indicating increased erythropoietic activity. Severe anemia negatively regulates hepcidin 
production through the action of erythroferrone,36 even in the presence of 
inflammation/infection37, 38 or sickle cell disease.39 Inflammation, as measured by ferritin and 
CRP, did not differ between the SMA and CM groups, although parasite density, known to 
correlate with hepcidin levels,40 was higher in CM. In agreement with previous studies,41, 42 
we found higher hepcidin levels in children with severe malaria compared to those with 
asymptomatic parasitemia. This is likely to be due to increased inflammation in severe 
malaria, rather than the older age of the community-based children, since older children 
would be expected to have higher hepcidin levels than younger children.26, 43  
 
Iron is an essential nutrient for bacterial growth and ex-vivo studies suggest that increased 
serum iron levels may stimulate the growth of various bacteria including Salmonella 
Typhimurium.44, 45 In mouse models, reduced hepcidin levels are associated with increased 
susceptibility to NTS infections,18 although little is known about the role of hepcidin during 
NTS and malaria infections in children. In the current study, children with SMA+NTS had 
lower hepcidin levels and hepcidin/ferritin ratios than those with NTS alone; although sTfR, 
CRP and ferritin levels did not differ between these groups. High hepcidin levels would be 
expected in children with NTS bacteremia since hepcidin is known to increase in response to 
inflammation and infection. A challenge infection study with Salmonella enterica Typhi in 




vitro and murine studies also show that Salmonella Typhimurium may directly or indirectly 
upregulate hepcidin expression and perturb iron regulatory pathways.20  
 
Hepcidin concentrations may alter iron availability within the Salmonella-containing vacuole 
(SCV). Recent evidence indicates that hepcidin leads to increased degradation of ferroportin 
on the SCV, and limits the movement of iron into the SCV. 21 However, this conflicts with an 
earlier report that ferroportin transports iron out of the SCV,47 and these contradictions may 
be based on differences in experimental systems used.48 It also remains controversial whether 
iron accumulation in the SCV may promote bacterial growth by increasing iron availability,19, 
22 or kill bacteria through the Fenton reaction.21 Low hepcidin levels in mice with severe 
hemolytic anemia were associated with increased susceptibility to Salmonella Typhimurium 
infection and hepcidin treatment improved survival.18 We hypothesize that low hepcidin 
levels in children with SMA, and non-malaria severe anemia, might contribute to NTS 
bacteremia by increasing iron availability in the SCV for NTS growth together with other 
mechanisms (Figure 1). Surprisingly, sTfR levels were elevated in children with NTS alone 
despite higher hemoglobin levels. It is not known whether NTS might induce transcription of 
transferrin receptors to increase transferrin iron acquisition, since transferrin receptors have 
been observed on the SCV during early phases of NTS endocytosis in murine models.49  
 
To the best of our knowledge, this is the first study reporting hepcidin levels in children with 
NTS or with concomitant SMA and NTS bacteremia. The strengths of the study are that we 
utilized a very large 21-year dataset (n=75,034) with matching stored samples to identify and 
describe associations between severe malaria, NTS bacteremia and hepcidin in children. Our 
study also has important limitations. First, the study was observational, and as such, 




had few samples for children with SMA and NTS coinfection and no samples for those with 
CM and NTS coinfection since some samples were insufficient or missing, which may have 
introduced selection bias. Nonetheless, these are a unique sample set with accompanying 
clinical data collected over 21 years. Another limitation is that we did not measure additional 
parameters such as serum iron, transferrin saturation, and haptoglobin levels due to the 
volumes and availability of stored samples. Additionally, a few participants had sTfR 
concentrations above the cut-off values making it challenging to interpret findings from 
regression models for sTfR (Supplementary Table S3). Finally, our study was conducted in a 
single site. It is also possible that our study underestimated associations, considering the low 
sensitivity of blood cultures used to identify NTS. Nonetheless, this study complements the 
existing in vitro and animal data on the relationship between SMA and NTS bacteremia and 
provides preliminary evidence on the possible role of hepcidin in mediating this association.  
 
In conclusion, SMA was associated with a strongly increased risk of NTS bacteremia in 
children and reduced hepcidin levels were observed in children with SMA and SMA+NTS. 
The question of whether ferroportin transports iron into or out of the SCV remains an active 
area of research,21, 47 and future findings may support our hypothesis or generate new ideas 
on how low hepcidin might mediate NTS susceptibility in children with SMA. Further studies 
are needed to understand the role of the hepcidin-ferroportin axis in susceptibility to NTS in 
human subjects, how hepcidin and iron disturbances might mediate susceptibility to 
bacteremia due to NTS or other organisms, and how P. falciparum, iron deficiency or other 
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 Table 1.  Factors associated with non-typhoidal Salmonella bacteremia in all hospitalized 
children (n=75,034)  
Characteristic NTS, n (%) Hospital controls, n (%) OR (95% CI) 1 P1 
Clinical features     
Age, years (IQR) 1.07 (0.55, 1.90) 0.98 (0.18, 2.18) 1.01 (0.93, 1.08) 0.87 
Sex, male 224/400 (56.0) 42,226/74,633 (56.6) 0.98 (0.80, 1.19) 0.82 
Fever  267/369 (72.4) 37,886/61,979 (61.2) 1.66 (1.32, 2.09) <0.0001 
Diarrhea 2 126/400 (31.5) 14,187/74,615 (19.0) 1.96 (1.58, 2.42) <0.0001 
Vomiting  127/388 (32.7) 18,061/73,242 (24.7) 1.49 (1.20, 1.84) 0.0003 
Severe pneumonia 3 111/400 (27.8) 21,068/74,610 (28.2) 0.98 (0.78, 1.22) 0.83 
Very severe pneumonia 4 59/400 (14.8) 7,480/74,606 (10.0) 1.55 (1.18, 2.05) 0.002 
Underweight 5 204/340 (60.0) 28,479/68,661 (41.5) 2.12 (1.70, 2.63) <0.0001 
Stunting 6 198/371 (53.4) 27,812/69,510 (40.0) 1.72 (1.40, 2.11) <0.0001 
Wasting 7 180/380 (47.4) 19,493/67,493 (28.9) 2.22 (1.81, 2.71) <0.0001 
Laboratory characteristics     
Malaria slide positive 93/400 (23.3) 16,370/74,632 (21.9) 1.08 (0.85, 1.36) 0.52 
   SMA 8 38/393 (9.7) 2,253/74,223 (3.0) 3.42 (2.44, 4.79) <0.0001 
   Cerebral malaria 8,9 8/286 (2.7) 1,719/63,244 (2.7) 1.00 (0.50, 2.02) 0.99 
   Non-SMA malaria 48/400 (12.0) 13,708/74,632 (18.4) 0.61 (0.45, 0.82) 0.001 
Sickle cell disease 14/400 (3.7) 1,115/74,608 (1.5) 2.39 (1.40, 4.09) 0.002 
HIV positive 10 38/139 (27.3) 1,756/35,327 (5.0) 7.19 (4.94, 10.48) <0.0001 
Hb, g/dl (IQR) 7.4 (5.2, 9.4) 9.8 (8.1, 11.6) 1.28 (1.24, 1.32) <0.0001 
    Hb <5 g/dl 89/400 (22.3) 4,660/74,615 (6.2) 4.30 (3.39, 5.45) <0.0001 
    Hb 5-7 g/dl 11 86/311 (27.7) 6,575/69,974 (9.4) 3.69 (2.87, 4.73) <0.0001 
    Hb 7-10 g/dl 12 147/225 (65.3) 27,867/63,399 (44.0) 2.40 (1.83, 3.16) <0.0001 
Severe anemia without malaria13 44/400 (11.0) 1,997/74,634 (2.7) 4.50 (3.28, 6.17) <0.0001 
Abbreviations: NTS, non-typhoidal Salmonella; n/N, number positive/number tested; OR, odds ratio; 
CI, confidence interval; SMA, severe malaria anemia; and CM, cerebral malaria; Hb, hemoglobin; 
and HIV, human immunodeficiency virus. 1Odds ratios and P values were derived from univariable 
logistic regression models; 2Passage of three or more loose or liquid stools within 24 hours; 3History 
of cough or difficulty in breathing plus lower chest wall indrawing; 4Cough or difficulty breathing 
plus either prostration, lethargy, hypoxia, loss of consciousness, or a history of convulsions; 5Weight-
for-age z-score < –2; 6Height-for-age z-score <–2; 7Weight-for-height z-score <–2 or mid-upper arm 
circumference <12.5 cm in children >6 months of age using WHO Child Growth Standards50; 




children with Blantyre coma scale scores were included; 10Data was available from February 2005 
after routine HIV testing was introduced thus analyses included a limited number of children (n = 
35,466); 11Excludes children with hemoglobin levels <5 g/dl; 12Excludes children with hemoglobin 




Table 2. Hepcidin and biomarkers of iron status and inflammation in a sub-study of 
hospitalized and community-based children 
Biomarker Group n Medians (IQR) P1 
Hepcidin, ng/ml SMA and NTS coinfection 16 9.3 (4.7, 49.8) Reference 
Severe malaria anemia 33 31.1 (5.5, 61.2) 0.43 
NTS bacteremia 33 105.8 (17.3, 233.3) 0.02 
Cerebral malaria 34 90.7 (38.7, 176.1) 0.004 
Asymptomatic malaria 49 6.5 (2.0, 13.1) 0.16 
Healthy controls 242 3.8 (1.2, 12.6) 0.01 
Ferritin, µg/L SMA and NTS coinfection 16 311.5 (241, 392) Reference 
Severe malaria anemia 32 348.5 (296, 384) 0.55 
NTS bacteremia 29 356.0 (203, 397) 0.76 
Cerebral malaria 28 370.0 (359, 393) 0.23 
Asymptomatic malaria 48 30.5 (17.0, 53.0) <0.0001 
Healthy controls 237 16.0 (8.0, 26.0) <0.0001 
Hepcidin/ferritin 
ratio2 
SMA and NTS coinfection 16 0.03 (0.01, 0.22) Reference 
Severe malaria anemia 32 0.10 (0.03, 0.19) 0.53 
NTS bacteremia 29 0.31 (0.06, 0.66) 0.007 
Cerebral malaria 28 0.24 (0.14, 0.69) 0.01 
Asymptomatic malaria 48 0.19 (0.09, 0.46) 0.01 
Healthy controls 232 0.27 (0.08, 0.66) 0.0006 
sTfR, mg/L SMA and NTS coinfection 16 48.1 (36.8, 66.9) Reference 
Severe malaria anemia 33 43.3 (30.1, 61.3) 0.64 
NTS bacteremia 32 38.3 (30.9, 67.6) 0.50 
Cerebral malaria 33 31.2 (23.9, 45.5) 0.02 
Asymptomatic malaria 49 3.8 (2.7, 4.9) <0.0001 
Healthy controls 239 3.6 (2.8, 4.8) <0.0001 
CRP, mg/L SMA and NTS coinfection 16 117.5 (79.0, 145.0) Reference 
Severe malaria anemia 33 120.0 (79.2, 152.7) 0.80 
NTS bacteremia 33 104.3 (35.1, 162.4) 0.67 
Cerebral malaria 33 120.9 (57.8, 150.9) 0.93 
Asymptomatic malaria 48 1.0 (0.3, 7.1) <0.0001 




Abbreviations: IQR, interquartile range; SMA, severe malaria anemia; NTS, non-typhoidal 
Salmonella; CRP, C-reactive protein; sTfR, soluble transferrin receptor; and n/a, data not 
available.  1P values were derived using pairwise Wilcoxon rank sum test. 2Hepcidin/ferritin 






Figure 1. The hepcidin-link between severe malarial anemia (SMA) and non-typhoidal 
Salmonella (NTS) bacteremia. Low hepcidin levels in children with SMA may contribute to 
the risk of NTS bacteremia. (A) During malaria infection, proinflammatory responses and 
parasitemia induce the expression of hepcidin, the main iron regulatory hormone. Hepcidin 
degrades ferroportin (FPN) on the macrophage membrane and the Salmonella containing 
vacuole (SCV),21 resulting in decreased iron availability for NTS bacteria. The bacteria may 
also utilize other iron acquisition strategies such as transferrin through transferrin receptors 
(TfR) in early endosomes. Proinflammatory responses, including production of interleukin 
(IL)-6 and interferon-gamma (IFN-γ), mediate killing of NTS through formation of reactive 
oxygen species (ROS) and other pathways. (B) In SMA, increased hemolysis and 
erythropoietic drive induce production of erythroferrone (ERFE),36 a hormone that 
downregulates hepcidin synthesis. This results in increased expression of FPN on the surface 
of the macrophage and the SCV.21 Heme from hemolyzed parasitized red blood cells (pRBC) 
and the haptoglobin-hemoglobin (Hp-Hb) complex is broken down by heme oxygenase-1 
(HO-1) into equimolar amounts of iron, biliverdin and carbon monoxide. HO-1 and heme-
breakdown products downregulate immune responses and promote an anti-inflammatory 
environment.15 The net effect of low hepcidin, increased HO-1, SMA-induced anti-
inflammatory cytokines such as IL-10 and increased intra-SCV iron levels is increased 
proliferation of NTS bacteria. DMT-1 denotes divalent metal transporter 1; and Cp, 
ceruloplasmin. Red arrows indicate direction of increase or decrease; dotted lines indicate 
reduced activity.  
 
Figure 2. Selection of study participants. All children aged ≤60 months with complete age 
and hemoglobin data admitted between August 1998 and October 2019 were included in the 
retrospective epidemiological analysis. Children with concomitant severe malaria and non-
typhoidal Salmonella (NTS), and whose specimens were available in the Kilifi biobank, were 
enrolled into the iron and hepcidin sub-study. Each child was then matched with two 
hospitalized children with NTS alone, severe malaria anemia (SMA) alone, and cerebral 
malaria (CM) alone based on age and sex. 
 
Figure 3. Iron and inflammatory biomarkers in children with malaria. Circulating levels 




(sTfR), (E) C-reactive protein (CRP), and (F) hemoglobin in children with malaria. P values 
from pairwise comparisons were determined by the Wilcoxon rank-sum test. ‘NS’ indicates P 
> 0.05. AM, asymptomatic malaria; CM, cerebral malaria; SMA, severe malaria anemia. 
 
Figure 4. Iron and inflammatory biomarkers in children with severe malaria anemia 
(SMA) and/or non-typhoidal Salmonella (NTS) bacteremia. Circulating levels of (A) 
hepcidin, (B) ferritin, (C) hepcidin/ferritin ratio, (D) soluble transferrin receptors (sTfR), (E) 
C-reactive protein (CRP), and (F) hemoglobin in children with SMA and/or NTS bacteremia. 
P values from pairwise comparisons were determined by the Wilcoxon rank-sum test. ‘NS’ 
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Sickle cell diagnosis 
DNA was extracted retrospectively from frozen samples collected at admission by use of 
Qiagen DNA blood mini kits (Qiagen, Crawley, UK) and typed for sickle-cell disease by 
polymerase chain reaction (PCR) as previously described.1, 2  
 
Iron and inflammatory biomarker assays 
We assayed hepcidin (Hepcidin-25 [human] EIA kit; Bachem), soluble transferrin receptor 
(sTfR; enzyme-linked immunosorbent assay; R&D systems), ferritin (micro-particle enzyme 
immunoassay, IMx [MEIA] ferritin assay, Abbott Laboratories), complete blood count 
(Beckman Coulter) and C-reactive protein (CRP, Dade Dimension particle enhanced 
turbidimetric immunoassay; Hitachi Corp.) according to manufacturers guidelines and as 
previously described.3 Hepcidin/ferritin ratio was calculated by dividing hepcidin (ng/ml) by 
ferritin (µg/L).    
 
Statistical analyses 
To examine factors associated with risk of NTS bacteremia, we used univariable logistic 
regression models, and a stepwise backward selection approach eliminating factors with 
P>0.1 after each step and retaining those with P<0.05 in the final multivariable logistic 
regression models. Variables defined by hemoglobin levels (including severe anemia, SMA, 
and severe anemia without malaria) were included in separate models for the multivariable 
analyses.Year of admission was included as a covariate in the final models. Wasting and 
stunting were dropped out of the final models because of collinearity with underweight. HIV 
status was not included in the final multivariable models due to many missing values, but 
remained a significant predictor of NTS bacteraemia in analyses restricted to children with 




Supplementary Table S1. Sample selection for the hepcidin sub-study across the years 
 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Total 
SMA+NTS 1 10 2 0 0 1 0 1 0 0 0 0 1 0 16 
SMA 4 4 1 0 0 8 3 7 5 0 0 0 1 0 33 
NTS 3 5 3 0 1 9 0 2 3 2 1 0 3 1 33 
CM 1 0 0 1 1 9 5 0 10 7 0 0 0 0 34 





Supplementary Table S2. Stepwise-selection multivariable logistic regression of factors associated with non-typhoidal Salmonella bacteremia 
in all hospitalized children (n=75,034) 
Characteristic1 SMA-restricted model All severe anemia– restricted model Severe anemia without malaria – 
restricted model 
 Adj OR (95% CI) 2 Adj P 2 Adj OR (95% CI) 2 Adj P 2 Adj OR (95% CI) 2 Adj P 2 
SMA 2.17 (1.44, 3.28) 0.0002     
Severe anaemia (Hb <5 g/dl)    3.15 (2.36, 4.20) <0.0001   
Severe anemia without malaria     4.03 (2.78, 5.84) <0.0001 
Age, years  0.88 (0.80, 0.97) 0.009 0.87 (0.79, 0.96) 0.004 0.88 (0.80, 0.97) 0.009 
Fever (temperature >37.5⁰C) 1.89 (1.46, 2.45) <0.0001 1.85 (1.43, 2.39) <0.0001 1.85 (1.43, 2.39) <0.0001 
Diarrhea 3 1.58 (1.22, 2.03) 0.0004 1.65 (1.28, 2.11) 0.0001 1.54 (1.20, 1.97) 0.0007 
Very severe pneumonia 4 1.54 (1.12, 2.12) 0.008 1.46 (1.06, 2.01) 0.02 1.53 (1.12, 2.10) 0.008 
Underweight 5 2.19 (1.74, 2.76) <0.0001 2.06 (1.64, 2.59) <0.0001 2.10 (1.67, 2.64) <0.0001 
Sickle cell disease 2.55 (1.33, 4.88) 0.005 1.97 (1.03, 3.78) 0.04   
Abbreviations: OR, odds ratio; CI, confidence interval; SMA, severe malaria anemia. 1Only factors with P<0.05 in the final models are shown. SMA, severe 
anaemia, and severe anemia without malaria were included in separate models. 2Adjusted odds ratios and P-values from a stepwise backward selection 
logistic regression model retaining variables with P<0.1 in each step, and including variables with P<0.05 in the final models. Year of admission was also 
adjusted in the final models. HIV status was not included in the final multivariable models due to many missing values, but remained a significant predictor of 
NTS bacteraemia in analyses restricted to children with HIV diagnosis (adj. OR 5.07 [95% CI 3.14, 8.19]; P<0.0001 in the SMA model); 3Passage of three or 
more loose or liquid stools within 24 hours;  4Cough or difficulty breathing plus either prostration, lethargy, hypoxia, loss of consciousness, or a history of 
convulsions; 5Weight-for-age z-score < –2 using WHO Child Growth Standards.
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Supplementary Table S3. Demographic and clinical characteristics of children in the hepcidin sub-study with measurements of iron and 
inflammation 
Characteristic Hospitalized children  Community children1 
SMA and NTS (%)  SMA (%) NTS (%) CM (%) AM (%) Healthy controls (%) 
Age, months (IQR) 2 23.6 (11.4, 31.6) 22.3 (16.6, 30.3) 17.2 (5.5, 28.5) 23.0 (13.6, 36.4) 63.2 (40.1, 77.4) 41.6 (21.7, 64.2) 
Sex, male 8/16 (50.0) 15/33 (45.5) 20/33 (60.6) 13/34 (38.2) 27/49 (55.1) 134/242 (55.4) 
Fever 3 7/16 (43.8) 21/33 (63.6) 18/32 (56.3) 25/34 (73.5) 3/21 (14.3) 5/88 (5.7) 
Hemoglobin 3.2 (2.7, 4.2) 4.0 (3.4, 4.4) 7.3 (6.4, 9.8) 7.5 (5.9, 8.2) n/a n/a 
Vomiting 7/16 (43.8) 16/33 (18.2) 9/33 (27.2) 10/33 (30.3) n/a n/a 
Wasting 9/16 (56.3) 8/33 (28.2) 15/32 (45.5) 8/32 (23.5) n/a n/a 
Stunting 9/16 (56.3) 13/30 (43.3) 14/29 (48.3) 14/31 (45.2) n/a n/a 
Underweight 7/12 (58.3) 11/32 (34.3) 20/29 (69.0) 16/34 (47.1) n/a n/a 
Pallor 4 5/5 (100) 24/25 (96.0) 10/27 (37.0) 20/33 (60.6) n/a n/a 
Coma (BCS <3) 0/3 (0) 5/24 (20.8) 1/22 (4.6) 34/34 (100.0) n/a n/a 
HIV status, positive 5 0/1 (0) 2/9 (22.2) 2/9 (18.2) 0/17 (0) n/a n/a 
Transfused 14/16 (87.5) 19/33 (57.6) 3/33 (9.1) 9/34 (26.5) n/a n/a 
In-hospital mortality 4/16 (25.0) 3/33 (9.1) 8/33 (24.2) 4/34 (11.8) n/a n/a 
Abbreviations: SMA, severe malaria anemia; NTS, non-typhoidal Salmonella; CM, cerebral malaria; AM, asymptomatic malaria; IQR, interquartile range; 
BCS, Blantyre coma score; and HIV, human immunodeficiency virus. 1Only age, gender and axillary temperature data were available for community 
children. 2 Medians and interquartile ranges are presented. 3Temperature >37.5⁰C. 4Pallor was defined clinically. 5HIV data was only available for children 
admitted between 2005-2019. 
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Supplementary Table S4. Geometric means and linear regression analyses of iron and/or 
inflammatory biomarkers by hospital groups. 
Biomarker Group n Geometric means (95% CI) Adj β (95% CI) 1 Adj P1 
Log-hepcidin, ng/ml SMA and NTS 16 11.7 (4.0, 34.5) Reference  
SMA 33 21.4 (12.4, 36.8) 0.47 (-0.73, 1.67) 0.44 
NTS 33 48.7 (20.3, 116.4) 1.99 (0.81, 3.26) 0.001 
CM 34 62.9 (37.2, 106.4) 1.52 (0.13, 2.92) 0.03 
Log-ferritin, µg/L SMA and NTS 16 287.0 (233.4, 352.9) Reference  
SMA 32 329.3 (280.7, 386.4) 0.26 (-0.08, 0.61) 0.14 
NTS 29 268.6 (193.8, 372.3) 0.22 (-0.12, 0.56) 0.20 
CM 28 305.5 (226.8, 411.5) 0.37 (-0.03, 0.77) 0.07 
Log-hepcidin/ferritin SMA and NTS 16 0.04 (0.01, 0.12) Reference  
SMA 32 0.07 (0.04, 0.12) 0.15 (-1.04, 1.35) 0.80 
NTS 29 0.18 (0.08, 0.40) 1.56 (0.38, 2.74) 0.01 
CM 28 0.20 (0.11, 0.38) 1.03 (-0.37, 2.43) 0.15 
Log-sTfR, mg/L2 SMA and NTS 16 46.2 (36.5, 58.6) Reference  
SMA 33 42.8 (35.7, 51.4) -0.19 (-0.52, 0.14) 0.25 
NTS 32 40.6 (32.6, 50.4) -0.23 (-0.55, 0.09) 0.16 
CM 33 33.9 (29.8, 40.0) -0.40 (-0.78, -0.01) 0.04 
Log-CRP, mg/L SMA and NTS 16 98.4 (72.9, 132.9) Reference  
SMA 33 96.7 (76.6, 122.0) -0.04 (-0.72, 0.63) 0.90 
NTS 30 77.2 (51.7, 115.1) -0.26 (-0.92, 0.39) 0.43 
CM 33 76.2 (51.6, 112.7) -0.34 (-1.12, 0.44) 0.39 
Log-parasite density, 
parasites/µl 
SMA and NTS 16 9.1 x103 (3.0 x103, 2.8 x104) Reference  
SMA 33 5.1 x104 (2.4 x104, 1.1 x104) 1.49 (0.09, 2.90) 0.04 
CM 33 1.9 x105 (1.1 x105, 3.2 x105) 2.87 (1.12, 4.60) 0.002 
Abbreviations: SMA, severe malaria anaemia; NTS, non-typhoidal Salmonella bacteremia; sTfR, 
soluble transferrin receptors; CRP, and C-reactive protein. 1Adjusted coefficients (adj β) and P-values 
were derived from a linear regression model adjusting for inflammation (log-CRP) and year of 
admission; 2Twelve sTfR values were above the upper limit of the assay (>84 mg/L) and were 
recorded as 84 mg/L for this analysis. These values were distributed across the groups as follows: 
SMA and NTS (2), SMA (5), NTS (2) and CM (3).  
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Supplementary Table S5. Correlation of hepcidin with iron and inflammatory biomarkers in 
hospitalized children  
 All groups SMA and NTS SMA NTS CM 
Variable r  P  r  P r  P  r  P  r  P  
Ferritin, µg/L 0.38 <0.0001 0.10 0.69 0.37 0.04 0.58 0.001 0.21 0.28 
sTfR, mg/L 1 -0.37 <0.0001 -0.08 0.77 -0.43 0.01 -0.34 0.06 -0.21 0.24 
CRP, mg/L 0.31 0.0007 0.24 0.37 0.63 0.0001 0.44 0.01 0.02 0.91 
Hemoglobin, g/dL 0.37 <0.0001 0.32 0.23 0.28 0.11 -0.07 0.70 0.20 0.25 
Parasite density, 
parasites/µl 
0.44 <0.0001 -0.08  0.77 0.53 0.001   0.29 0.09 
Abbreviations: SMA, severe malaria anemia; NTS, non-typhoidal Salmonella bacteremia; CM, 
cerebral malaria; sTfR, soluble transferrin receptors; CRP, C-reactive protein; and r, pairwise non-
parametric Spearman’s correlation coefficients. 1Twelve sTfR values were above the upper limit of 
the assay (>84 mg/L) and were recorded as 84 mg/L for this analysis. These values were distributed 
across the groups as follows: SMA and NTS (2), SMA (5), NTS (2) and CM (3). 
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Supplementary Figure S1 
 
 




Supplementary Figure S2 
 
Supplementary Figure S2. Proportions of admissions (in percentage) due to non-typhoidal 




Supplementary Figure S3 
 
Supplementary Figure S3. Forest plot showing association between SMA and the risk of various 
organisms causing bacteraemia in hospitalized children. Odds ratios were derived from univariable 
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